Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Taylor, C. Mojica, T. Olson, P. Woods, B. Johnson (Rochester, United States Of America). Systemic hypoxia contributes to pulmonary hypertension in heart failure. Eur Respir J 2011; 38: Suppl. 55, 1518

Member's Comments

No comment yet.

Related content which might interest you: Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension Source: Eur Respir J 2011; 37: 472 Year: 2011 Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 770 Year: 2009 Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease Source: Eur Respir Rev 2011; 20: 236-242 Year: 2011 Right heart failure in pulmonary hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Pulmonary hypertension in chronic lung disease and hypoxia Source: Eur Respir J, 53 (1) 1801914; 10.1183/13993003.01914-2018 Year: 2019 Plasma big-endothelin and hemodynamics in patients with pulmonary arterial hypertension compared to patients with chronic left heart failure with and without pulmonary venous hypertension Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 1286-1293 Year: 2010 Apelin improves cardiac output in patients with pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Acute vasodilator response in different forms of pre-capillary pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 Fluid-challenge testing to distinguish PAH from pulmonary hypertension secondary to heart failure Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Reduced pulmonary vascular response to hypoxia is associated with endothelial dysfunction in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 173s Year: 2001 Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients Source: Eur Respir J 2004; 24 : 580-586 Year: 2004 The effect of chronic dosing of riociguat on acute hypoxic pulmonary vasoconstriction in respiratory disease Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Systemic consequences of pulmonary arterial hypertension Source: International Congress 2019 – State of the art session: Pulmonary vascular diseases Year: 2019 Pulmonary hypertension in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 892-905 Year: 2003